Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.37
HSP's Cash to Debt is ranked lower than
78% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. HSP: 0.37 )
Ranked among companies with meaningful Cash to Debt only.
HSP' s 10-Year Cash to Debt Range
Min: 0.08   Max: N/A
Current: 0.37

Equity to Asset 0.53
HSP's Equity to Asset is ranked lower than
64% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. HSP: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
HSP' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.65
Current: 0.53

0.28
0.65
Interest Coverage 6.04
HSP's Interest Coverage is ranked lower than
83% of the 362 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2145.51 vs. HSP: 6.04 )
Ranked among companies with meaningful Interest Coverage only.
HSP' s 10-Year Interest Coverage Range
Min: 0.19   Max: 9999.99
Current: 6.04

0.19
9999.99
F-Score: 7
Z-Score: 4.70
M-Score: -2.62
WACC vs ROIC
10.84%
8.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.90
HSP's Operating margin (%) is ranked higher than
60% of the 647 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.81 vs. HSP: 10.90 )
Ranked among companies with meaningful Operating margin (%) only.
HSP' s 10-Year Operating margin (%) Range
Min: 0.41   Max: 16.17
Current: 10.9

0.41
16.17
Net-margin (%) 7.43
HSP's Net-margin (%) is ranked higher than
56% of the 647 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.76 vs. HSP: 7.43 )
Ranked among companies with meaningful Net-margin (%) only.
HSP' s 10-Year Net-margin (%) Range
Min: -0.23   Max: 11.4
Current: 7.43

-0.23
11.4
ROE (%) 10.35
HSP's ROE (%) is ranked higher than
62% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. HSP: 10.35 )
Ranked among companies with meaningful ROE (%) only.
HSP' s 10-Year ROE (%) Range
Min: -0.31   Max: 24.74
Current: 10.35

-0.31
24.74
ROA (%) 5.28
HSP's ROA (%) is ranked higher than
59% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. HSP: 5.28 )
Ranked among companies with meaningful ROA (%) only.
HSP' s 10-Year ROA (%) Range
Min: -0.16   Max: 13.13
Current: 5.28

-0.16
13.13
ROC (Joel Greenblatt) (%) 18.04
HSP's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.39 vs. HSP: 18.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HSP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 0.67   Max: 53.84
Current: 18.04

0.67
53.84
Revenue Growth (3Y)(%) 2.20
HSP's Revenue Growth (3Y)(%) is ranked lower than
62% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. HSP: 2.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HSP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.9   Max: 12.4
Current: 2.2

-0.9
12.4
EBITDA Growth (3Y)(%) 29.60
HSP's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. HSP: 29.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HSP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -32.3   Max: 29.6
Current: 29.6

-32.3
29.6
» HSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

HSP Guru Trades in Q2 2014

Mario Gabelli 204,370 sh (+32.91%)
Jim Simons 182,900 sh (+20.49%)
Michael Price 400,000 sh (unchged)
Robert Bruce 10,000 sh (unchged)
Vanguard Health Care Fund 8,375,170 sh (unchged)
Jeff Auxier 181,463 sh (-11.71%)
John Rogers 3,130,809 sh (-24.15%)
Paul Tudor Jones 7,700 sh (-28.70%)
» More
Q3 2014

HSP Guru Trades in Q3 2014

Joel Greenblatt 313,242 sh (New)
Paul Tudor Jones 24,894 sh (+223.30%)
Jim Simons 323,100 sh (+76.65%)
Mario Gabelli 254,870 sh (+24.71%)
Vanguard Health Care Fund 8,375,170 sh (unchged)
Michael Price 400,000 sh (unchged)
Robert Bruce 10,000 sh (unchged)
John Rogers 2,433,369 sh (-22.28%)
Jeff Auxier 127,307 sh (-29.84%)
» More
Q4 2014

HSP Guru Trades in Q4 2014

Jim Simons 631,695 sh (+95.51%)
Mario Gabelli 352,370 sh (+38.25%)
Michael Price 400,000 sh (unchged)
Robert Bruce 10,000 sh (unchged)
Joel Greenblatt Sold Out
Jeff Auxier 126,907 sh (-0.31%)
Vanguard Health Care Fund 7,966,970 sh (-4.87%)
John Rogers 2,311,309 sh (-5.02%)
Paul Tudor Jones 19,798 sh (-20.47%)
» More
Q1 2015

HSP Guru Trades in Q1 2015

Jeremy Grantham 657,484 sh (New)
Mario Gabelli 834,303 sh (+136.77%)
Michael Price 400,000 sh (unchged)
Robert Bruce 10,000 sh (unchged)
John Rogers Sold Out
Vanguard Health Care Fund Sold Out
Jeff Auxier 57,665 sh (-54.56%)
Paul Tudor Jones 5,652 sh (-71.45%)
Jim Simons 93,800 sh (-85.15%)
» More
» Details

Insider Trades

Latest Guru Trades with HSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Hospira Inc

John Rogers Comments on Hospira Inc. - Jul 25, 2013

Injectible drug specialist Hospira, Inc. (HSP) shot up +16.69% on good and surprising news about a new compound. Specifically, its Inflectra drug—a biosimilar medicine to Remicade— was recommended for approval by a crucial European authority for multiple treatments. In Europe, it is likely to be approved to treat rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. Typically, a drug is only approved for one condition first and then may receive other indications over time. Given Remicade had sales of roughly $2 billion in Europe last year, this was huge news. In recent quarters, there has been such a tight focus on existing facilities and historical problems that few have looked to the future. Our point of view has been the issues will get fixed and the company will go on to create new and better compounds to continue to drive growth; it seems the market needed a reminder such a future was even possible.

From John RogersAriel Fund Second Quarter 2013 Commentary.


Check out John Rogers latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 44.60
HSP's P/E(ttm) is ranked lower than
62% of the 530 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.90 vs. HSP: 44.60 )
Ranked among companies with meaningful P/E(ttm) only.
HSP' s 10-Year P/E(ttm) Range
Min: 8.48   Max: 133.97
Current: 44.6

8.48
133.97
Forward P/E 26.53
HSP's Forward P/E is ranked lower than
67% of the 426 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.96 vs. HSP: 26.53 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 44.60
HSP's PE(NRI) is ranked lower than
59% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.70 vs. HSP: 44.60 )
Ranked among companies with meaningful PE(NRI) only.
HSP' s 10-Year PE(NRI) Range
Min: 8.48   Max: 135
Current: 44.6

8.48
135
P/B 4.40
HSP's P/B is ranked lower than
59% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. HSP: 4.40 )
Ranked among companies with meaningful P/B only.
HSP' s 10-Year P/B Range
Min: 1.52   Max: 5.83
Current: 4.4

1.52
5.83
P/S 3.32
HSP's P/S is ranked lower than
54% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. HSP: 3.32 )
Ranked among companies with meaningful P/S only.
HSP' s 10-Year P/S Range
Min: 0.99   Max: 3.35
Current: 3.32

0.99
3.35
PFCF 157.80
HSP's PFCF is ranked lower than
85% of the 438 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.02 vs. HSP: 157.80 )
Ranked among companies with meaningful PFCF only.
HSP' s 10-Year PFCF Range
Min: 8.32   Max: 203.78
Current: 157.8

8.32
203.78
POCF 27.85
HSP's POCF is ranked lower than
52% of the 444 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.56 vs. HSP: 27.85 )
Ranked among companies with meaningful POCF only.
HSP' s 10-Year POCF Range
Min: 5.95   Max: 50.76
Current: 27.85

5.95
50.76
EV-to-EBIT 32.73
HSP's EV-to-EBIT is ranked lower than
59% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.90 vs. HSP: 32.73 )
Ranked among companies with meaningful EV-to-EBIT only.
HSP' s 10-Year EV-to-EBIT Range
Min: -1403.5   Max: 508.2
Current: 32.73

-1403.5
508.2
Shiller P/E 83.30
HSP's Shiller P/E is ranked lower than
82% of the 414 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.08 vs. HSP: 83.30 )
Ranked among companies with meaningful Shiller P/E only.
HSP' s 10-Year Shiller P/E Range
Min: 12.62   Max: 83.3
Current: 83.3

12.62
83.3
Current Ratio 2.48
HSP's Current Ratio is ranked higher than
54% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. HSP: 2.48 )
Ranked among companies with meaningful Current Ratio only.
HSP' s 10-Year Current Ratio Range
Min: 1.61   Max: 3.03
Current: 2.48

1.61
3.03
Quick Ratio 1.43
HSP's Quick Ratio is ranked lower than
58% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. HSP: 1.43 )
Ranked among companies with meaningful Quick Ratio only.
HSP' s 10-Year Quick Ratio Range
Min: 1   Max: 2.04
Current: 1.43

1
2.04
Days Inventory 148.96
HSP's Days Inventory is ranked lower than
67% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.86 vs. HSP: 148.96 )
Ranked among companies with meaningful Days Inventory only.
HSP' s 10-Year Days Inventory Range
Min: 47.38   Max: 139.51
Current: 148.96

47.38
139.51
Days Sales Outstanding 47.40
HSP's Days Sales Outstanding is ranked higher than
71% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.43 vs. HSP: 47.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSP' s 10-Year Days Sales Outstanding Range
Min: 43.91   Max: 59.38
Current: 47.4

43.91
59.38

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.90
HSP's Price/Tangible Book is ranked lower than
63% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. HSP: 6.90 )
Ranked among companies with meaningful Price/Tangible Book only.
HSP' s 10-Year Price/Tangible Book Range
Min: 3.04   Max: 20.95
Current: 6.9

3.04
20.95
Price/DCF (Projected) 3.50
HSP's Price/DCF (Projected) is ranked higher than
50% of the 485 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. HSP: 3.50 )
Ranked among companies with meaningful Price/DCF (Projected) only.
HSP' s 10-Year Price/DCF (Projected) Range
Min: 0.91   Max: 3.45
Current: 3.5

0.91
3.45
Price/Median PS Value 1.70
HSP's Price/Median PS Value is ranked lower than
57% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. HSP: 1.70 )
Ranked among companies with meaningful Price/Median PS Value only.
HSP' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 1.68
Current: 1.7

0.61
1.68
Price/Graham Number 3.70
HSP's Price/Graham Number is ranked lower than
58% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. HSP: 3.70 )
Ranked among companies with meaningful Price/Graham Number only.
HSP' s 10-Year Price/Graham Number Range
Min: 1.85   Max: 9.99
Current: 3.7

1.85
9.99
Earnings Yield (Greenblatt) 3.10
HSP's Earnings Yield (Greenblatt) is ranked higher than
58% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.00 vs. HSP: 3.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
HSP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 10
Current: 3.1

0.2
10
Forward Rate of Return (Yacktman) -4.84
HSP's Forward Rate of Return (Yacktman) is ranked lower than
75% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.59 vs. HSP: -4.84 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
HSP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.6   Max: 18.4
Current: -4.84

-1.6
18.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HOS.Germany,
Hospira Inc was incorporated in Delaware on September 16, 2003. The Company is a provider of injectable drugs and infusion technologies, and is also engaged in developing, manufacturing, marketing and distribution. Its portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company's business segments are Specialty Injectable Pharmaceuticals, Medication Management and Other Pharmaceuticals. Specialty Injectable Pharmaceuticals consists of generic injectable pharmaceuticals products. Generic injectable pharmaceuticals provide customers with a lower-cost alternative to branded products when associated patent protection expires, when patents are declared invalid, or when the generic products do not infringe the patents of others. Our generic injectable pharmaceuticals are sold in therapeutic areas including analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other. Medication Management offer the Hospira MedNet safety software system, which is designed for hospitals to customize intravenous drug dosage limits and track drug delivery to prevent medication errors. The wireless network version of the Hospira MedNet system establishes real-time send-and-receive capability and can interface with select hospital and pharmacy information systems. Other Pharmaceuticals primarily consists of large volume I.V. solutions, nutritionals and contract manufacturing services. We offer infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for washing and cleansing of wounds or surgical sites. The Company's primary customers include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its competitors include Baxter International Inc.; Becton, Dickinson and Company; Fresenius Kabi AG; Mallinckrodt plc; Mylan Inc; Par Pharmaceuticals Companies, Inc.; Pfizer Inc.; Sandoz; Sanofi S.A. and Teva Pharmaceuticals, Aspen Medical; Fresenius Kabi; Pfizer; Sandoz and a number of smaller competitors and the originator companies. The Company's operations and business activities are subject to extensive legal and regulatory requirements that are enforced by numerous governmental agencies in the countries in which it do business.
» More Articles for HSP

Headlines

Articles On GuruFocus.com

More From Other Websites
10 companies with the biggest earnings surprises May 22 2015
How biotechs are affecting J&J's business May 20 2015
Hospira, Alliance for Health Reform Bring Food and Drug Administration, Industry Experts Together to... May 20 2015
Hospira, Alliance for Health Reform Bring Food and Drug Administration, Industry Experts Together to... May 20 2015
20 / 05 / 2015 : THERADIAG AND HOSPIRA SIGN A PARTNERSHIP AGREEMENT May 20 2015
Drug maker Endo strikes again with $8bn bid for US rival May 18 2015
Barclays: Pfenex Is Worth $28/Share May 18 2015
Hospira–Pfizer Deal Update: Shareholder Approval, 2nd Request May 14 2015
Hospira Shareholders Approve Merger of Hospira and Pfizer at Special Meeting May 13 2015
Hospira Shareholders Approve Merger of Hospira and Pfizer at Special Meeting May 13 2015
HOSPIRA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 13 2015
HOSPIRA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 12 2015
How the Mylan Bid Stacks Up to Similar Transactions May 11 2015
Weak Q1 Earnings Have Some Investors Worried.......Should You Be? May 04 2015
HOSPIRA INC Financials May 01 2015
Hospira Statement On FDA's Final Biosimilar Guidance Documents May 01 2015
Mylan Shareholders Well Placed in the Mylan–Teva Deal Apr 30 2015
10-Q for Hospira, Inc. Apr 30 2015
Mylan Bumps Up Offer for Perrigo Apr 29 2015
The Perrigo–Mylan Proposal Faces some Big Hurdles Apr 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK